TheraRadar
Clinical-Stage Companies / Palatin Technologies

Palatin Technologies

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 8/5/2024

9
Total Trials
3
Phase 3
6
Phase 2
2
Recruiting
93
Score

Pipeline by Phase

Phase 3
3
Phase 2
6
Phase 1

Therapeutic Focus

Hypoactive Sexual Desire Disorder Heart Failure With Preserved Ejection Fraction Obesity Ulcerative Colitis Ulcerative Colitis Acute

Clinical Trials (9)

NCT05201170 Phase 3 COMPLETED

A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye

Started: 12/30/2021

NCT02333071 Phase 3 COMPLETED

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Started: 12/1/2014

NCT02338960 Phase 3 COMPLETED

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Started: 1/1/2015

NCT04318145 Phase 2 TERMINATED

Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects

Started: 11/12/2020

NCT06565611 Phase 2 ACTIVE NOT RECRUITING

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

Started: 8/5/2024

NCT05466890 Phase 2 ACTIVE NOT RECRUITING

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Started: 9/15/2022

NCT05709444 Phase 2 COMPLETED

A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Started: 12/26/2022

NCT01382719 Phase 2 COMPLETED

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

Started: 6/1/2011

NCT00686803 Phase 2 COMPLETED

Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension

Started: 4/1/2008

Drug Candidates

PL-3994 Aqueous Intravenous Solution Dose Ascention PL-3994 Aqueous Intravenous Solution Single Dose bremelanotide tirzepatide PL8177 Placebo PL8177 Bremelanotide RAAS inhibition therapy Vehicle Ophthalmic Solution PL9643 Ophthalmic Solution
Activity Status: Slowing
Last Trial Started: 8/5/2024
Last Trial Ended: 4/26/2024
Trials (12 months): 0
Completed Trials: 6
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.